Clinical Trials Logo
  1. Home
  2. Diabetes Mellitus, Type 2
  3. NCT01950650
  4. Details
NCT01950650 Clinical Trial

GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus

Diabetes Mellitus, Type 2 Clinical Trial

Official title:
GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01950650
Other study ID # GAPP1
Secondary ID U1111-1136-2507
Status Completed
Phase N/A
First received September 23, 2013
Last updated April 25, 2017
Start date March 2010
Est. completion date September 2010

Study information
Verified date April 2017
Source Novo Nordisk A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is conducted in Asia, Europe and in the United States of America. The aim of this study is to examine patient and physician beliefs regarding insulin therapy and the degree to which patients adhere to their insulin regimens.

Recruitment information / eligibility
Status Completed
Enrollment 1800
Est. completion date September 2010
Est. primary completion date September 2010
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- PATIENTS WITH DIABETES:

- Age 18 years or older

- Treated with insulin

- Type 1 or Type 2 diabetes

- PHYSICIANS:

- In practice for more than 1 year since completing residency

- See a minimum number of patients with diabetes per week (primary care physicians 5, specialists 10)

- Initiate insulin treatment for patients with diabetes

Study Design

Related Conditions & MeSH terms

Intervention

Behavioral:
• No treatment given
Survey conducted through computer-assisted telephone interviewing.
• survey
Survey conducted via the Internet.

Locations
Country Name City State
China Novo Nordisk Investigational Site Beijing Beijing
France Novo Nordisk Investigational Site Paris La défense cedex
Germany Novo Nordisk Investigational Site Mainz
India Novo Nordisk Investigational Site Bangalore
Japan Novo Nordisk Investigational Site Tokyo
Russian Federation Novo Nordisk Investigational Site Moscow
Spain Novo Nordisk Investigational Site Madrid
Turkey Novo Nordisk Investigational Site Istanbul
United Kingdom Novo Nordisk Investigational Site Crawley
United States Novo Nordisk Investigational Site Princeton New Jersey

Sponsors (1)
Lead Sponsor Collaborator
Novo Nordisk A/S

Countries where clinical trial is conducted

United States,  China,  France,  Germany,  India,  Japan,  Russian Federation,  Spain,  Turkey,  United Kingdom, 

References & Publications (1)

Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012 May;29(5):682-9. doi: 10.1111/j.1464-5491.2012.036 — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Frequency of insulin omission/non-adherence In the past 30 days prior to the day when responding to the survey (patient survey)
Primary Reasons for insulin omission/non-adherence reported by patient and physician Day 1 (when responding to the survey)
Secondary Impact of insulin treatment on life domains (patient survey) Day 1 (when responding to the online questionnaire)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2

External Links